Lassogen

Lassogen is a private, preclinical-stage biotech founded in 2016 and based in San Diego, leveraging a proprietary platform to engineer lasso peptides into a new therapeutic modality. The company's Lassotides™ are designed to target intracellular and extracellular disease drivers that are difficult to address with existing antibody or small molecule drugs, offering potential advantages in stability, selectivity, and oral bioavailability. With a platform that integrates computational design, synthetic biology, and evolution, Lassogen is building a pipeline focused initially on oncology while exploring other therapeutic areas. The company appears to be pre-revenue and is in the process of advancing its lead candidates toward clinical development.

A proprietary platform for discovering and engineering lasso peptides (Lassotides™). It integrates a curated database of >100,000 lasso genes, cell-free biosynthesis for rapid production, computational design, evolution libraries, and synthetic biology for manufacturing scale-up.

Lassogen competes in the crowded field of novel therapeutic modalities, including other engineered peptide, macrocycle, and protein degradation platforms. Its differentiation hinges on the unique structural stability and tunability of the lasso scaffold. Success depends on demonstrating clinical advantages over existing antibodies, small molecules, and competing peptide technologies.